Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

E2F-dependent repression of topoisomerase II regulates heterochromatin formation and apoptosis in cells with melanoma-prone mutation.

Cancer research - 15 May 2005

Jiao Wan, Lin Huei-Min, Timmons Jamie, Nagaich Akhilesh K, Ng Shu-Wing, Misteli Tom, Rane Sushil G

Abstract excerpt

RB pathway mutations, especially at the CDK4 and INK4A loci, are hallmarks of melanomagenesis. It is presently unclear what advantages these alterations confer during melanoma progression and how they influence melanoma therapy. Topoisomerase II inhibitors are widely used to treat human malignancies, including melanoma, although their variable success is attributable to a poor understanding of their mechanism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinases

Share to Doxorubicin

Share to E2F Transcription Factors

Share to Etoposide

Share to Heterochromatin

Share to Topoisomerase II Inhibitors

Source

Identifiers

PMID: 15899796
DOI: 10.1158/0008-5472.CAN-04-3999

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

E2F-dependent repression of topoisomerase II regulates heterochromatin formation and apoptosis in cells with melanoma-prone mutation.PMID 15899796Read ↗

PSMD14 drives melanoma cell survival and MAPK inhibitor resistance through histone H2A deubiquitinationSemantic proximity Read ↗

Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?Semantic proximity Read ↗

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanomaSemantic proximity Read ↗

No longer a molecular black box--new clues to apoptosis and drug resistance in melanoma.Semantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignanciesSemantic proximity Read ↗

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathwaySemantic proximity Read ↗

<i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibitionSemantic proximity Read ↗

Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.Semantic proximity Read ↗

E2F1 plays a direct role in Rb stabilization and p53-independent tumor suppression.Semantic proximity Read ↗

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In VivoSemantic proximity Read ↗

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.